Duane Reade Q3
This article was originally published in The Rose Sheet
Executive Summary
Sales for the third quarter were up 8.2% to $338.6 mil., approximately $11.4 mil. below the company's previous expectations due to economic weakness and slowing growth rate of the prescription sector, retailer announces Oct. 6. The announcement was made ahead of an Oct. 23 Q3 earnings call. Northeast power outage in August resulted in a sales loss of about $3.3 mil., the firm notes. Same store sales for the period improved 3%, with pharmacy same store sales increasing 8.6% and front-end same store sales declining 1.1%. Sales performance during Q3 combined with economic impact have lowered net income to about $.08-$.09 per diluted share versus original expectations of $.15-$.20 per diluted share, retailer adds. Annual sales are now expected to be about $1.39 bil., while diluted EPS will be between $.55-$.61...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.